2025
Board and Management Transition
08/09/2025PromarkerEso precisely detects early stage esophageal cancer
27/08/2025Annual Report to Shareholders
27/08/2025Appendix 4G and Corporate Governance Statement
27/08/2025Preliminary Final Report
28/07/2025Quarterly Activities Report June 2025 – Appendix 4C
24/07/2025Next-Gen PromarkerD test performance results published
14/07/2025OxiDx test detects muscle damage in thoroughbred racehorses
08/07/2025Application for quotation of securities
07/07/2025Notification of cessation of securities
04/07/2025Top 20 Holders and Range of Units for Attaching Options
04/07/2025Application for quotation of securities
03/07/2025AMA grants reimbursement code for Next-Gen PromarkerD test
01/07/2025Funding boost for precision diagnostics Proteomics Facility
30/06/2025First patent for endometriosis blood test – granted in Japan
23/06/2025Next-gen PromarkerD test system released for predicting DKD
20/06/2025PromarkerD launched into the US at major diabetes conference
13/06/2025Change of Director’s Interest Notices x 4
06/06/2025Proposed issue of securities
06/06/2025Supplementary Prospectus
05/06/2025A landmark in non-invasive Esophageal Cancer diagnosis
05/06/2025$12 million capital raise completed with oversubscribed SPP
30/05/2025Results of Extraordinary General Meeting
26/05/2025PromarkerEndo latest results presented at world congress
15/05/2025Chinese patent granted for OxiDx technology
05/05/2025Share Purchase Plan Offer Booklet
02/05/2025Notice of Extraordinary General Meeting/Proxy Form
29/04/2025Notice Under Section 708A
29/04/2025Notification regarding unquoted securities
29/04/2025Application for quotation of securities
28/04/2025Target Market Determination
28/04/2025Options Prospectus
24/04/2025Quarterly Activities Report March 2025 – Appendix 4C
22/04/2025Proteomics to raise $4.5m through Placement
10/04/2025Investor Presentation – JMM Biotech Forum
08/04/2025Investor Presentation Morgan Stanley Alpha ex-100 Conference
07/04/2025Proteomics appoints Clinical Advisory Board for PromarkerEso
28/03/2025Australian patent granted for OxiDx oxidative stress test
20/03/2025Investor Presentation – Broker Meets Biotech
13/03/2025PromarkerD predictive test for DKD launched in Australia
11/03/2025PromarkerD outperforms conventional tests – results published
28/02/2025Proteomics opens CLIA certified reference laboratory in USA
26/02/2025Interim Financial Report and Appendix 4D
04/02/2025Investor Presentation – Euroz Hartleys Healthcare Forum
31/01/2025Change of Company Secretary
21/01/2025Quarterly Activities Report December 2024 – Appendix 4C
